Molecular Diagnostics Market

Molecular Diagnostics Market by Product & Service(Reagents, Kits, PoC & Tabletop Instruments), Application(COVID-19, Hepatitis, HAI, HIV, Oncology, Genetic Tests), Technology (PCR, NGS, ISH), End User (Hospitals, Diagnostic Labs)-Global Forecast to 2026

Report Code: MD 2521 Apr, 2021, by marketsandmarkets.com

[272 Pages Report] The global molecular diagnostics market size is projected to reach USD 31.8 billion by 2026 from USD 17.8 billion in 2021, at a CAGR of 12.3%. Market growth is driven by the increasing prevalence of infectious diseases and cancer, the rising funding for R&D, the increase in PoC testing devices and technological advancements.

Molecular Diagnostics Market

To know about the assumptions considered for the study, download the pdf brochure

COVID-19 Impact on Global Molecular Diagnostics Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the molecular diagnostics market because of the use of molecular diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to infectious disease has become a pressing medical issue worldwide. In addition to the development of vaccines and therapeutic drugs, there is a growing call for the development of more precise and simple testing technologies and the expansion of testing structures. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products. Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities

Market Dynamics

Driver: Increasing prevalence of infectious diseases and cancer

The increasing prevalence of infectious diseases and cancer in developed and developing regions will positively influence the growth of the molecular diagnostics market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for molecular diagnostic tests. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for molecular diagnostics during the forecast period. These tests are performed by molecular diagnostics; hence, it is expected to have a positive impact on this market.

Opportunity: The growing significance of companion diagnostics

Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic products can significantly alter the drug development process and commercialize drug candidates by yielding safer drugs with enhanced therapeutic efficacy quickly and cost-effectively. With an increase in the demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics has high growth potential. The growing importance of companion diagnostics is also providing growth opportunities for the molecular diagnostics market. Pharmaceutical companies are increasingly collaborating with diagnostic companies to make safer and more effective drugs. The growing availability of such advanced and efficient companion diagnostic tests is expected to support market growth in the coming years.

Restraint: The high cost of instruments

A molecular diagnostic instrument is expensive. The variable costs of the reagents needed, and those fixed by the suppliers thereof, add to the overall expenditure. Furthermore, maintenance and insurance, laboratory supervision, and overhead costs (including utilities, space, and administration) are also additional expenses. The high-volume of molecular diagnostic instruments may be affordable only for large hospitals and reference laboratories with good capital budgets. Most small laboratories, physician’s offices, and sole practitioners have no capital budgets and may not be able to afford a large or very large-sized analyzer. Thus, high-cost requirements might restrain the growth of the molecular diagnostics market.

In 2020, reagents & kits segment accounted for the largest share of the molecular diagnostics market, by product & service

Based on product, the molecular diagnostics market is segmented into into reagents & kits, instruments, and services & software. In 2020, the reagents & kits segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

In 2020, polymerase chain reaction (PCR) segment accounted for the largest share in the market, by technology

The molecular diagnostics market is segmented into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), in situ hybridization (ISH), DNA sequencing and next-generation sequencing (NGS), DNA microarray, and other technologies based on test type. In 2020, the polymerase chain reaction (PCR) segment accounted for the largest share. This can be attributed to the growing use of PCR in proteomics and genomics, use of RT-PCR in COVID-19 test, automation of PCR instruments, and the emergence of advanced technologies like qRT-PCR drive this segment's growth.

North America is the largest regional market for molecular diagnostics

The global molecular diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global molecular diagnostics market. The North American molecular diagnostics market's growth can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.

Molecular Diagnostics Market  by Region

Some key players in the molecular diagnostics market (2021- 2026)

  • Roche Diagnostics Ltd.
  • Hologic, Inc.
  • bioMιrieux SA
  • Abbott Laboratories
  • QIAGEN

Scope of the report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD Billion)

Segments covered

Product & Service, technology, application, end user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

F. Hoffmann-La Roche Ltd(Switzerland), Hologic, Inc. (US), bioMιrieux SA (France), Abbott Laboratories (US), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Myriad Genetics Inc. (US), Illumina Inc. (US), Agilent Technologies Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A (Italy), Grifols S.A. (Spain), Quidel Corporation(US), Genetic Signatures (Australia), MDxHealth, Inc. (US), Exact Sciences Corporation (US), Biocartis NV (Belgium), TBG Diagnostics Ltd. (Australia), GenMark Diagnostics Inc. (US), Luminex Corporation (US), HTG Molecular Diagnostics Inc. (US), Vela Diagnostics (Singapore), Amoy Diagnostics Co., Ltd. (China), Molbio Diagnostics Pvt. Ltd. (India), ELITechGroup (France), Savyon Diagnostics Ltd. (Israel), ABACUS Diagnostica Oy (Finland), and geneOmbio Technologies Pvt. Ltd. (India).

This report categorizes the molecular diagnostics market into the following segments and subsegments:

By Product

  • Reagents & kits
  • Instruments
    • Tabletop Instruments
    • Portable & PoC Instruments
  • Services & Software

By Technology

  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • DNA Sequencing & Next-Generation Sequencing (NGS)
  • In Situ Hybridization (ISH)
  • DNA Microarrays
  • Other technologies

By Application

  • Infectious Disease Diagnostics
    • COVID-19
    • Hepatitis
    • HIV
    • CT/NG
    • HAI
    • HPV
    • Tuberculosis
    • Influenza
    • Other Infectious Diseases
  • Oncology Testing
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Other Cancers
  • Genetic Tests
  • Other Applications

By End User

  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe (RoE)
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America (RoLATAM)
    • Middle East & Africa

Recent Developments

  • In Januray 2021, Hologic, Inc. acquired Biotheranostics Inc. (US) to expand its molecular diagnostics portfolio.
  • In May 2020, Roche Diagnostics acquired Stratos Genomics (US) to complement the development of it’s nanopore technology and gives access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX).
  • In March 2020, Abbott Laboratories launched the ID NOW PoC testing system.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 33)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           FIGURE 1 INCLUSIONS & EXCLUSIONS
           1.2.1 MARKETS COVERED
           FIGURE 2 MOLECULAR DIAGNOSTICS MARKET
           1.2.2 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 38)
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           FIGURE 3 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Key data from primary sources
                    2.2.2.2 Key industry insights
           FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
           FIGURE 5 MOLECULAR DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
           FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
           FIGURE 7 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 COVID-19 HEALTH ASSESSMENT
    2.7 COVID-19 ECONOMIC ASSESSMENT
    2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
    2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE MOLECULAR DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 52)
           FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
           FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
           FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
           FIGURE 15 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
           FIGURE 16 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 56)
    4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
           FIGURE 17 THE RISING ADOPTION OF POC DIAGNOSTICS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
    4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
           FIGURE 18 THE REAGENTS & KITS SEGMENT IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT & SERVICE, IN 2021
    4.3 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
           FIGURE 19 THE PCR SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
    4.4 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026
           FIGURE 20 THE DIAGNOSTIC LABORATORIES SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE END USER MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 59)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 21 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 The increasing prevalence of infectious diseases and cancer
                    5.2.1.2 Rising focus on R&D and funding in molecular diagnostics
                    5.2.1.3 Increasing awareness for early disease diagnosis in developing countries
                    5.2.1.4 Rising technological advancements in molecular diagnostics
                    5.2.1.5 Increasing use of PoC diagnostic tests
           5.2.2 RESTRAINT
                    5.2.2.1 Unfavorable reimbursement scenario
                    5.2.2.2 The high cost of instruments
           5.2.3 OPPORTUNITIES
                    5.2.3.1 The growing significance of companion diagnostics
                    5.2.3.2 Growth opportunities in emerging countries
           5.2.4 CHALLENGES
                    5.2.4.1 Changing regulatory landscape
                    5.2.4.2 Operational barriers
                    5.2.4.3 The introduction of alternative technologies
           5.2.5 COVID 19 IMPACT ANALYSIS
    5.3 PRICING ANALYSIS
           TABLE 1 PRICING ANALYSIS OF MOLECULAR DIAGNOSTIC PRODUCTS (2021)
    5.4 PATENT ANALYSIS
    5.5 VALUE CHAIN ANALYSIS
           FIGURE 22 VALUE CHAIN ANALYSIS OF THE MOLECULAR DIAGNOSTICS MARKET
    5.6 SUPPLY CHAIN ANALYSIS
           FIGURE 23 SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS
    5.8 PORTER’S FIVE FORCES ANALYSIS
           FIGURE 24 PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT FROM NEW ENTRANTS
           5.8.2 THREAT FROM SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
    5.9 PESTLE ANALYSIS
    5.10 REGULATORY LANDSCAPE
           5.10.1 NORTH AMERICA
                    5.10.1.1 US
                    5.10.1.2 Canada
           5.10.2 EUROPE
           5.10.3 ASIA PACIFIC
                    5.10.3.1 China
                    5.10.3.2 Japan
                    5.10.3.3 India
           5.10.4 LATIN AMERICA
                    5.10.4.1 Brazil
                    5.10.4.2 Mexico
           5.10.5 MIDDLE EAST
           5.10.6 AFRICA
    5.11 TRADE ANALYSIS
           5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
                    5.11.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million)
                    5.11.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons)
    5.12 TECHNOLOGY ANALYSIS

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 77)
    6.1 INTRODUCTION
           TABLE 2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
    6.2 REAGENTS & KITS
           6.2.1 THE RECURRENT PURCHASE OF REAGENTS & KITS IS A MAJOR FACTOR DRIVING MARKET GROWTH
           TABLE 3 REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
    6.3 INSTRUMENTS
           TABLE 4 INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 5 INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           6.3.1 TABLETOP INSTRUMENTS
                    6.3.1.1 The outbreak of COVID-19 and rising incidences of cancer drives the growth of this segment
           TABLE 6 TABLETOP INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           6.3.2 PORTABLE & POC INSTRUMENTS
                    6.3.2.1 The increasing adoption of PoC technologies drives the growth of this segment
           TABLE 7 PORTABLE & POC INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
    6.4 SERVICES & SOFTWARE
           6.4.1 THE GROWING UPTAKE OF ADVANCED INSTRUMENTS IN THE MOLECULAR DIAGNOSTICS MARKET DRIVES SEGMENT GROWTH
           TABLE 8 SERVICES & SOFTWARE MARKET, BY REGION, 2019–2026 (USD MILLION)

7 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 84)
    7.1 INTRODUCTION
           TABLE 9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    7.2 POLYMERASE CHAIN REACTION (PCR)
           7.2.1 THE GROWING USE OF PCR IN PROTEOMICS AND GENOMICS IS A MAJOR GROWTH DRIVER FOR THIS SEGMENT
           TABLE 10 PCR TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
           7.3.1 THE COST-BENEFITS OF THIS TECHNOLOGY IS A KEY FACTOR DRIVING THE MARKET GROWTH
           TABLE 11 INAAT TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
           7.4.1 INCREASING USE OF NGS IN THE DIAGNOSIS OF CANCER IS A GROWTH DRIVER FOR THIS SEGMENT
           TABLE 12 DNA SEQUENCING & NGS TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.5 IN SITU HYBRIDIZATION (ISH)
           7.5.1 THE RISING PREVALENCE OF CANCER AND GENETIC DISORDERS IS A KEY FACTOR DRIVING SEGMENT GROWTH
           TABLE 13 ISH TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.6 DNA MICROARRAY
           7.6.1 THE INTRODUCTION OF DNA MICROARRAY HAS ACCELERATED GENE EXPRESSION AND DISEASE DIAGNOSIS
           TABLE 14 DNA MICROARRAY TECHNOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.7 OTHER TECHNOLOGIES
           TABLE 15 OTHER TECHNOLOGIES MARKET, BY REGION, 2019–2026 (USD MILLION)

8 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 92)
    8.1 INTRODUCTION
           TABLE 16 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    8.2 INFECTIOUS DISEASE DIAGNOSTICS
           TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           8.2.1 COVID-19
                    8.2.1.1 The outbreak of the pandemic is a key factor driving market growth
           TABLE 19 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 20 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
           8.2.2 HEPATITIS
                    8.2.2.1 The global prevalence of hepatitis is a key factor driving market growth
           TABLE 21 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 22 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION ASSAYS)
           8.2.3 CT/NG
                    8.2.3.1 CT/NG infections are the most commonly prevalent STDs; key factor driving the market growth
           TABLE 23 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 24 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
           8.2.4 HIV
                    8.2.4.1 The increasing number of blood transfusions & donations will drive the market growth for this segment
           TABLE 25 HIV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 26 HIV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
           8.2.5 HAI
                    8.2.5.1 The rising burden of MRSA infections is a key factor driving the market growth for this segment
           TABLE 27 HAI DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 28 HAI DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
           8.2.6 HPV
                    8.2.6.1 Technological advancements such as rapid HPV diagnostics to drive the market growth for this segment
           TABLE 29 HPV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 30 HPV DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
           8.2.7 TUBERCULOSIS
                    8.2.7.1 The increasing burden of TB globally to drive the market growth of this segment
           TABLE 31 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 32 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
           8.2.8 INFLUENZA
                    8.2.8.1 The rising focus on containing the spread of influenza drives the market growth for this segment
           TABLE 33 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 34 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)
           8.2.9 OTHER INFECTIOUS DISEASES
           TABLE 35 OTHER INFECTIOUS DISEASES MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.3 ONCOLOGY TESTING
           TABLE 36 ONCOLOGY TESTING MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 37 ONCOLOGY TESTING MARKET, BY TYPE, 2019–2026 (USD MILLION)
           8.3.1 BREAST CANCER
                    8.3.1.1 The increasing prevalence of breast cancer is a key driver for market growth
           TABLE 38 ONCOLOGY TESTING MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
           8.3.2 COLORECTAL CANCER
                    8.3.2.1 The rising focus on the development of companion diagnostic assays drives the market growth
           TABLE 39 ONCOLOGY TESTING MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION)
           8.3.3 LUNG CANCER
                    8.3.3.1 Increasing research for lung cancer biomarkers to drive the market growth
           TABLE 40 ONCOLOGY TESTING MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
           8.3.4 PROSTATE CANCER
                    8.3.4.1 Advancements in genomic technologies for the development of new biomarkers drive the market growth
           TABLE 41 ONCOLOGY TESTING MARKET FOR PROSTATE CANCER, BY REGION, 2019–2026 (USD MILLION)
           8.3.5 OTHER CANCERS
           TABLE 42 OTHER CANCER DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.4 GENETIC TESTS
           8.4.1 GENETIC TESTING ENABLES THE DIAGNOSIS OF VARIOUS DISEASES
           TABLE 43 GENETIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.5 OTHER APPLICATIONS
           TABLE 44 OTHER APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)

9 MOLECULAR DIAGNOSTICS MARKET, BY END USER (Page No. - 112)
    9.1 INTRODUCTION
           TABLE 45 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.2 DIAGNOSTIC LABORATORIES
           9.2.1 INCREASING OUTSOURCING OF ACTIVITIES TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVES MARKET GROWTH
           TABLE 46 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
    9.3 HOSPITALS AND CLINICS
           9.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING MARKET GROWTH
           TABLE 47 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2019–2026 (USD MILLION)
    9.4 OTHER END USERS
           TABLE 48 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)

10 MOLECULAR DIAGNOSTICS MARKET, BY REGION (Page No. - 116)
     10.1 INTRODUCTION
           TABLE 49 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
           FIGURE 25 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
           TABLE 50 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 51 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 52 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 53 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 54 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 The increasing prevalence of infectious diseases and cancer is a key factor expected to drive market growth in the US
           TABLE 55 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 56 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 57 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 58 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 The availability of funding for genomics research in Canada drives the market growth
           TABLE 59 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 60 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 61 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 62 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.3 EUROPE
           TABLE 63 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 64 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 65 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 66 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 67 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany
           TABLE 68 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 69 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 70 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 71 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.2 ITALY
                        10.3.2.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
           TABLE 72 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 73 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 74 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 75 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rising R&D expenditure in France to drive the market growth
           TABLE 76 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 77 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 78 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 79 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.4 RUSSIA
                        10.3.4.1 Increasing access to quality healthcare will support market growth in Russia
           TABLE 80 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 81 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 82 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 83 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 The increasing demand for genetic testing is expected to drive market growth in Spain
           TABLE 84 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 85 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 2019–2026 (USD MILLION)
           TABLE 86 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 87 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.6 UK
                        10.3.6.1 The increasing number of accredited diagnostic laboratories propels market growth for molecular diagnostics in the UK
           TABLE 88 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 89 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 90 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 91 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.7 REST OF EUROPE
           TABLE 92 ROE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 93 ROE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 94 ROE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 95 ROE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
           FIGURE 26 APAC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
           TABLE 96 APAC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 97 APAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 98 APAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 99 APAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 100 APAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth
           TABLE 101 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 102 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 103 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 104 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
           TABLE 105 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 106 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 107 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 108 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
           TABLE 109 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 110 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 111 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 112 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.4 AUSTRALIA
                        10.4.4.1 The prevalence of infectious diseases in Australia is a key driver for market growth
           TABLE 113 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 114 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 115 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 116 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC (ROAPAC)
           TABLE 117 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 118 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 119 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 120 ROAPAC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
           TABLE 121 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 122 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 123 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 124 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 125 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 Improving healthcare infrastructure in Brazil to drive the growth of the molecular diagnostics market
           TABLE 126 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 127 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 128 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 129 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 The improving accessibility and affordability of healthcare services to drive market growth for molecular diagnostics
           TABLE 130 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 131 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 132 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 133 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
           TABLE 134 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 135 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 136 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 137 ROLATAM: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST AND AFRICA
           TABLE 138 MEA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
           TABLE 139 MEA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 140 MEA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 141 MEA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 163)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
     11.4 MARKET SHARE ANALYSIS
           FIGURE 28 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYERS (2020)
             11.4.1 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY TECHNOLOGY
                        11.4.1.1 Polymerase Chain Reaction (PCR)
           FIGURE 29 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
                        11.4.1.2 DNA Sequencing and NGS
           FIGURE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING AND NGS, MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
                        11.4.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
           TABLE 142 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY KEY PLAYERS, 2020
                        11.4.1.4 In Situ Hybridization (ISH)
           TABLE 143 GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR ISH, BY KEY PLAYERS, 2020
             11.4.2 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY APPLICATION
                        11.4.2.1 Infectious Disease Applications
           TABLE 144 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET RANKING, BY KEY PLAYERS, 2020
     11.5 COMPETITIVE LEADERSHIP MAPPING
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
           FIGURE 31 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
     11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME (2020)
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
           FIGURE 32 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SME, 2019
     11.7 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS
           FIGURE 33 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE MOLECULAR DIAGNOSTICS MARKET
     11.8 COMPETITIVE SCENARIO
           FIGURE 34 MARKET EVALUATION MATRIX, 2018-2020
             11.8.1 MOLECULAR DIAGNOSTICS: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2018 – MARCH 2021)
           TABLE 145 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
             11.8.2 MOLECULAR DIAGNOSTICS: DEALS (JANUARY 2018 – MARCH 2021)
           TABLE 146 KEY DEALS
             11.8.3 MOLECULAR DIAGNOSTICS: OTHER DEVELOPMENTS (JANUARY 2018 – MARCH 2021)
           TABLE 147 OTHER KEY DEVELOPMENTS

12 COMPANY PROFILES (Page No. - 174)
     12.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, SWOT analysis, Right to Win)* 
             12.1.1 F. HOFFMANN-LA ROCHE LTD.
           TABLE 148 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
           FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
             12.1.2 HOLOGIC, INC.
           TABLE 149 HOLOGIC, INC.: BUSINESS OVERVIEW
           FIGURE 36 HOLOGIC, INC.: COMPANY SNAPSHOT (2020)
             12.1.3 BIOMΙRIEUX SA
           TABLE 150 BIOMΙRIEUX SA: BUSINESS OVERVIEW
           FIGURE 37 BIOMΙRIEUX SA: COMPANY SNAPSHOT (2020)
             12.1.4 ABBOTT LABORATORIES
           TABLE 151 ABBOTT LABORATORIES: BUSINESS OVERVIEW
           FIGURE 38 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
             12.1.5 QIAGEN
           TABLE 152 QIAGEN: BUSINESS OVERVIEW
           FIGURE 39 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
             12.1.6 THERMO FISHER SCIENTIFIC INC.
           TABLE 153 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
           FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
             12.1.7 ILLUMINA, INC.
           TABLE 154 ILLUMINA, INC.: BUSINESS OVERVIEW
           FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
             12.1.8 MYRIAD GENETICS INC.
           TABLE 155 MYRIAD GENETICS INC.: BUSINESS OVERVIEW
           FIGURE 42 MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2019)
             12.1.9 SIEMENS HEALTHINEERS AG
           TABLE 156 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
           FIGURE 43 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
             12.1.10 DANAHER CORPORATION
           TABLE 157 DANAHER CORPORATION: BUSINESS OVERVIEW
           FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
             12.1.11 GRIFOLS S.A.
           TABLE 158 GRIFOLS S.A.: BUSINESS OVERVIEW
           FIGURE 45 GRIFOLS S.A: COMPANY SNAPSHOT (2020)
             12.1.12 AGILENT TECHNOLOGIES INC.
           TABLE 159 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
           FIGURE 46 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2020)
             12.1.13 BECTON, DICKINSON AND COMPANY
           TABLE 160 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
           FIGURE 47 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             12.1.14 DIASORIN S.P.A
           TABLE 161 DIASORIN S.P.A: BUSINESS OVERVIEW
           FIGURE 48 DIASORIN S.P.A: COMPANY SNAPSHOT (2019)
     12.2 START UP/ SME PLAYERS
             12.2.1 QUIDEL CORPORATION
           TABLE 162 QUIDEL CORPORATION: BUSINESS OVERVIEW
           FIGURE 49 QUIDEL CORPORATION: COMPANY SNAPSHOT (2019)
             12.2.2 GENETIC SIGNATURES
           TABLE 163 GENETIC SIGNATURES: BUSINESS OVERVIEW
           FIGURE 50 GENETIC SIGNATURES: COMPANY SNAPSHOT (2020)
             12.2.3 MDX HEALTH
           TABLE 164 MDX HEALTH: BUSINESS OVERVIEW
           FIGURE 51 MDX HEALTH: COMPANY SNAPSHOT (2019)
             12.2.4 EXACT SCIENCES
           TABLE 165 EXACT SCIENCES: BUSINESS OVERVIEW
           FIGURE 52 EXACT SCIENCES: COMPANY SNAPSHOT (2019)
             12.2.5 BIOCARTIS NV
           TABLE 166 BIOCARTIS NV: BUSINESS OVERVIEW
           FIGURE 53 BIOCARTIS NV: COMPANY SNAPSHOT (2019)
             12.2.6 TBG DIAGNOSTICS LTD.
           TABLE 167 TBG DIAGNOSTICS LTD.: BUSINESS OVERVIEW
           FIGURE 54 TBG DIAGNOSTICS LTD.: COMPANY SNAPSHOT (2019)
             12.2.7 GENMARK DIAGNOSTICS INC.
           TABLE 168 GENMARK DIAGNOSTICS INC.: BUSINESS OVERVIEW
           FIGURE 55 GENMARK DIAGNOSTICS INC.: COMPANY SNAPSHOT (2019)
             12.2.8 LUMINEX CORPORATION
           TABLE 169 LUMINEX CORPORATION: BUSINESS OVERVIEW
           FIGURE 56 LUMINEX CORPORATION: COMPANY SNAPSHOT (2019)
             12.2.9 HTG MOLECULAR DIAGNOSTICS
           TABLE 170 HTG MOLECULAR DIAGNOSTICS: BUSINESS OVERVIEW
           FIGURE 57 HTG MOLECULAR DIAGNOSTICS: COMPANY SNAPSHOT (2019)
             12.2.10 VELA DIAGNOSTICS
           TABLE 171 VELA DIAGNOSTICS: BUSINESS OVERVIEW
             12.2.11 AMOY DIAGNOSTICS CO. LTD.
           TABLE 172 AMOY DIAGNOSTICS CO. LTD.: BUSINESS OVERVIEW
             12.2.12 MOLBIO DIAGNOSTICS PVT. LTD.
           TABLE 173 MOLBIO DIAGNOSTICS PVT. LTD.: BUSINESS OVERVIEW
             12.2.13 ELITECHGROUP
           TABLE 174 ELITECHGROUP: BUSINESS OVERVIEW
             12.2.14 SAVYON DIAGNOSTICS LTD.
           TABLE 175 SAVYON DIAGNOSTICS LTD.: BUSINESS OVERVIEW
             12.2.15 ABACUS DIAGNOSTICA OY
           TABLE 176 ABACUS DIAGNOSTICS OY: BUSINESS OVERVIEW
             12.2.16 GENEOMBIO TECHNOLOGIES PVT LTD.
           TABLE 177 GENEOMBIO TECHNOLOGIES PVT. LTD.: BUSINESS OVERVIEW
*Business overview, Products offered, Recent developments, SWOT analysis, Right to Win might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 265)
     13.1 INSIGHTS FROM INDUSTRY EXPERTS
     13.2 DISCUSSION GUIDE
     13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.4 AVAILABLE CUSTOMIZATIONS
     13.5 RELATED REPORTS
     13.6 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the molecular diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.  After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The following is a breakdown of the primary respondents:

Molecular Diagnostics Market   Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the molecular diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Molecular Diagnostics Market Size: Top-Down Approach

Molecular Diagnostics Market   Size, Top-Down Approach

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global molecular diagnostics market by product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze company developments such as acquisitions, product launches and approvals, expansions, and other developments in the molecular diagnostics market.
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Molecular Diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company profiles

  • Additional fifteen company profiles of players operating in the molecular diagnostics market
COVID-19

Get in-depth analysis of the COVID-19 impact on the Molecular Diagnostics Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Molecular Diagnostics Market

Request For Special Pricing
Report Code
MD 2521
Published ON
Apr, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Molecular Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home